Pang H - Search Results

1

ABCC3 as a marker for multidrug resistance in non-small cell lung cancer.

Zhao Y, Lu H, Yan A, Yang Y, Meng Q, Sun L, Pang H, Li C, Dong X, Cai L. Zhao Y, et al. Among authors: pang h. Sci Rep. 2013 Nov 1;3:3120. doi: 10.1038/srep03120. Sci Rep. 2013. PMID: 24176985 Free PMC article.

2

Knockdown of osteopontin chemosensitizes MDA-MB-231 cells to cyclophosphamide by enhancing apoptosis through activating p38 MAPK pathway.

Pang H, Cai L, Yang Y, Chen X, Sui G, Zhao C. Pang H, et al. Cancer Biother Radiopharm. 2011 Apr;26(2):165-73. doi: 10.1089/cbr.2010.0838. Cancer Biother Radiopharm. 2011. PMID: 21539449

3

Prognostic values of osteopontin-c, E-cadherin and β-catenin in breast cancer.

Pang H, Lu H, Song H, Meng Q, Zhao Y, Liu N, Lan F, Liu Y, Yan S, Dong X, Cai L. Pang H, et al. Cancer Epidemiol. 2013 Dec;37(6):985-92. doi: 10.1016/j.canep.2013.08.005. Epub 2013 Sep 5. Cancer Epidemiol. 2013. PMID: 24012693 Clinical Trial.

4

Baseline staging tests based on molecular subtype is necessary for newly diagnosed breast cancer.

Chen X, Sun L, Cong Y, Zhang T, Lin Q, Meng Q, Pang H, Zhao Y, Li Y, Cai L, Dong X. Chen X, et al. Among authors: pang h. J Exp Clin Cancer Res. 2014 Mar 17;33(1):28. doi: 10.1186/1756-9966-33-28. J Exp Clin Cancer Res. 2014. PMID: 24628817 Free PMC article.

5

Ang II-AT1R increases cell migration through PI3K/AKT and NF-κB pathways in breast cancer.

Zhao Y, Wang H, Li X, Cao M, Lu H, Meng Q, Pang H, Li H, Nadolny C, Dong X, Cai L. Zhao Y, et al. Among authors: pang h. J Cell Physiol. 2014 Nov;229(11):1855-62. doi: 10.1002/jcp.24639. J Cell Physiol. 2014. PMID: 24692224

6

Luminal (Her2 negative) prognostic index and survival of breast cancer patients.

Chen X, Cong Y, Pan L, Jiang Y, Meng Q, Sun L, Pang H, Zhao Y, Dong X, Cai L. Chen X, et al. Among authors: pang h. Cancer Epidemiol. 2014 Jun;38(3):286-90. doi: 10.1016/j.canep.2014.03.007. Epub 2014 Apr 13. Cancer Epidemiol. 2014. PMID: 24725965

7

USP22 promotes tumor progression and induces epithelial-mesenchymal transition in lung adenocarcinoma.

Hu J, Yang D, Zhang H, Liu W, Zhao Y, Lu H, Meng Q, Pang H, Chen X, Liu Y, Cai L. Hu J, et al. Among authors: pang h. Lung Cancer. 2015 Jun;88(3):239-45. doi: 10.1016/j.lungcan.2015.02.019. Epub 2015 Mar 10. Lung Cancer. 2015. PMID: 25907317

8

miRNA-378 reverses chemoresistance to cisplatin in lung adenocarcinoma cells by targeting secreted clusterin.

Chen X, Jiang Y, Huang Z, Li D, Chen X, Cao M, Meng Q, Pang H, Sun L, Zhao Y, Cai L. Chen X, et al. Among authors: pang h. Sci Rep. 2016 Jan 19;6:19455. doi: 10.1038/srep19455. Sci Rep. 2016. PMID: 26781643 Free PMC article.

9

Efficacy and Safety of Nedaplatin in Advanced Breast Cancer Therapy.

Pang H, Feng T, Lu H, Meng Q, Chen X, Shen Q, Dong X, Cai L. Pang H, et al. Cancer Invest. 2016;34(4):167-72. doi: 10.3109/07357907.2016.1144061. Epub 2016 Apr 8. Cancer Invest. 2016. PMID: 27057601

10

Knockdown of lncRNA H19 restores chemo-sensitivity in paclitaxel-resistant triple-negative breast cancer through triggering apoptosis and regulating Akt signaling pathway.

Han J, Han B, Wu X, Hao J, Dong X, Shen Q, Pang H. Han J, et al. Among authors: pang h. Toxicol Appl Pharmacol. 2018 Nov 15;359:55-61. doi: 10.1016/j.taap.2018.09.018. Epub 2018 Sep 20. Toxicol Appl Pharmacol. 2018. PMID: 30244121

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

2,664 results

Search Page

Filters